EXPE vs FOLD · P/E 20, rev $13.69B vs rev $528.3M
Expedia Group Inc. (EXPE) versus Amicus Therapeutics Inc (FOLD) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Amicus Therapeutics Inc (FOLD) is a biotechnology company listed on US.
Latest reported EXPE revenue for 2024-12-31 was $13.69B. Net income was $1.22B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Latest reported FOLD revenue for 2024-12-31 was $528.3M. Net income was -$56.1M. Revenue was up 32.3% from 2023-12-31 to 2024-12-31. FOLD currently screens at market cap $1.80B.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. FOLD currently screens at market cap $1.80B.
Not investment advice. Open the EXPE and FOLD stock pages for the full models.
Not investment advice.